Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

Marzolini, C.; Kuritzkes, D.R.; Marra, F.; Boyle, A.; Gibbons, S.; Flexner, C.; Pozniak, A.; Boffito, M.; Waters, L.; Burger, D.; Back, D.; Khoo, S.

doi:10.7326/M22-0281

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

Détails

Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée

ID Serval

serval:BIB_70514994B951

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.

Collection

Publications

Institution

UNIL/CHUV

Titre

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

Périodique

Annals of internal medicine

Auteur⸱e⸱s

Marzolini C., Kuritzkes D.R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D., Back D., Khoo S.

ISSN

1539-3704 (Electronic)

ISSN-L

0003-4819

Statut éditorial

Publié

Date de publication

05/2022

Peer-reviewed

Oui

Volume

175

Numéro

Pages

744-746

Langue

anglais

Notes

Publication types: Editorial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

Nirmatrelvir–ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing such drug–drug interactions. An algorithm is provided to assist in decision making.

Mots-clé

COVID-19, Drug Interactions, Humans, Ritonavir/therapeutic use, SARS-CoV-2

URN

urn:nbn:ch:serval-BIB_70514994B9518

OAI-PMH

oai:serval.unil.ch:BIB_70514994B951

DOI

10.7326/M22-0281

Pubmed

35226530

Web of science

000767336200001